Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetraphenylporphyrin (TPP) is a synthetic heterocyclic compound belonging to the porphyrin family, characterized by four phenyl groups attached to the meso-positions of the porphine core. In biomedical research, TPP and its metallated derivatives (such as zinc, iron, or manganese complexes) are primarily developed as photosensitizers for photodynamic therapy (PDT). When exposed to specific wavelengths of light, TPP undergoes electronic excitation and transfers energy to molecular oxygen, generating highly reactive singlet oxygen and other reactive oxygen species (ROS). These ROS induce oxidative damage, leading to apoptosis or necrosis in targeted tissues, such as lung cancer cells or fungal pathogens. Beyond its therapeutic potential, TPP is utilized in tumor imaging, targeted drug delivery systems, and as a catalyst in various chemical processes including CO2 reduction and water electrolysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetraphenylporphyrin.